BACKGROUND: c-Fos is a cellular proto-oncogene which dimerizes with c-Jun proto-oncogene to form AP-1 transcription factor, which upregulates transcription of genes involved in proliferation and cancer formation. Four cardiac hormones, that is, long-acting natriuretic peptide (LANP), vessel dilator, kaliuretic peptide (KP) and atrial natriuretic peptide (ANP) with anticancer effects in vivo are potent inhibitors of the Ras-MEK 1/2-ERK 1/2 kinase cascade and signal transducer and activator of transcription-3 (STAT-3) that activate c-Fos and c-Jun. These four cardiac hormones were investigated for their effects on proto-oncogenes c-Fos and c-Jun within the nucleus of cancer cells. MATERIALS AND METHODS: Four cardiac hormones were evaluated for their ability to decrease proto-oncogenes c-Fos and c-Jun, measured by ELISA in extracted nuclei of three human cancer cell lines. RESULTS: Vessel dilator, LANP, KP and ANP over a concentration range of 100 pM-10 μM, maximally decreased c-Fos by 61%, 60%, 61% and 59% in human hepatocellular cancer cells, by 82%, 74%, 78% and 74% in small-cell lung cancer cells, and by 82%, 73%, 78% and 74% in human renal adenocarcinoma cells. c-Jun was maximally reduced by vessel dilator, LANP, KP and ANP by 43%, 31%, 61% and 35% in hepatocellular cancer cells, by 65%, 49%, 59% and 40% in small-cell lung cancer cells, and by 47%, 43%, 57% and 49% in renal cancer cells. CONCLUSION: Four cardiac hormones are potent inhibitors of c-Fos and c-Jun proto-oncogenes within the nucleus of cancer cells.
BACKGROUND:c-Fos is a cellular proto-oncogene which dimerizes with c-Jun proto-oncogene to form AP-1 transcription factor, which upregulates transcription of genes involved in proliferation and cancer formation. Four cardiac hormones, that is, long-acting natriuretic peptide (LANP), vessel dilator, kaliuretic peptide (KP) and atrial natriuretic peptide (ANP) with anticancer effects in vivo are potent inhibitors of the Ras-MEK 1/2-ERK 1/2 kinase cascade and signal transducer and activator of transcription-3 (STAT-3) that activate c-Fos and c-Jun. These four cardiac hormones were investigated for their effects on proto-oncogenes c-Fos and c-Jun within the nucleus of cancer cells. MATERIALS AND METHODS: Four cardiac hormones were evaluated for their ability to decrease proto-oncogenes c-Fos and c-Jun, measured by ELISA in extracted nuclei of three humancancer cell lines. RESULTS: Vessel dilator, LANP, KP and ANP over a concentration range of 100 pM-10 μM, maximally decreased c-Fos by 61%, 60%, 61% and 59% in humanhepatocellular cancer cells, by 82%, 74%, 78% and 74% in small-cell lung cancer cells, and by 82%, 73%, 78% and 74% in humanrenal adenocarcinoma cells. c-Jun was maximally reduced by vessel dilator, LANP, KP and ANP by 43%, 31%, 61% and 35% in hepatocellular cancer cells, by 65%, 49%, 59% and 40% in small-cell lung cancer cells, and by 47%, 43%, 57% and 49% in renal cancer cells. CONCLUSION: Four cardiac hormones are potent inhibitors of c-Fos and c-Jun proto-oncogenes within the nucleus of cancer cells.
Authors: José Tuñón; Javier Higueras; Nieves Tarín; Carmen Cristóbal; Óscar Lorenzo; Luis Blanco-Colio; José Luis Martín-Ventura; Ana Huelmos; Joaquín Alonso; Álvaro Aceña; Ana Pello; Rocío Carda; Dolores Asensio; Ignacio Mahíllo-Fernández; Lorenzo López Bescós; Jesús Egido; Jerónimo Farré Journal: PLoS One Date: 2015-06-05 Impact factor: 3.240
Authors: Roberto Martín-Reyes; Juan Antonio Franco-Peláez; Óscar Lorenzo; María Luisa González-Casaus; Ana María Pello; Álvaro Aceña; Rocío Carda; José Luis Martín-Ventura; Luis Blanco-Colio; María Luisa Martín-Mariscal; Juan Martínez-Milla; Ricardo Villa-Bellosta; Antonio Piñero; Felipe Navarro; Jesús Egido; José Tuñón Journal: PLoS One Date: 2016-05-12 Impact factor: 3.240
Authors: Simona Manuguerra; Cristóbal Espinosa Ruiz; Andrea Santulli; Concetta Maria Messina Journal: Int J Environ Res Public Health Date: 2019-02-18 Impact factor: 3.390